Loading
Life sciences · Journal article
Theoretical and Natural Science · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Although there have been some achievements in early detection and treatment, breast cancer is still a leading cause of cancer deaths among women worldwide. Due to differences in genes, signals, and how well they respond to treatment among the various types of breast cancer, there is frequently recurrence or resistance to therapy. The old candidate gene method and the RNAi screening method lack a priori knowledge and do not cover all gene interactions in the search for unknown gene regulatory factors. CRISPR-based functional genomics screening is a good way to study the functions of all the genes in the genome systematically. Both loss-of-function and gain-of-function types of CRISPR screening can be employed to find tumour-driving genes, drug-resistance factors and other good therapeutic targets. CRISPR has been applied to the screening of breast cancer in the discovery of driver genes, endocrine therapy resistance, chemotherapy resistance and other targeted therapy strategies. Problems and Future Directions of CRISPR Screening in Precision Medicine for Breast Cancer at Present are listed below.